Eli Lilly and - LLY Stock Forecast, Price & News

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Eli Lilly and Trading Up 2.1 %

LLY opened at $316.82 on Thursday. The firm has a 50 day simple moving average of $315.69 and a 200 day simple moving average of $292.69. Eli Lilly and has a fifty-two week low of $220.20 and a fifty-two week high of $335.33. The company has a market cap of $301.03 billion, a price-to-earnings ratio of 50.53, a price-to-earnings-growth ratio of 2.14 and a beta of 0.35. The company has a debt-to-equity ratio of 1.70, a current ratio of 1.10 and a quick ratio of 0.85.

Eli Lilly and (NYSE:LLY - Get Rating) last released its earnings results on Thursday, August 4th. The company reported $1.25 EPS for the quarter, missing analysts' consensus estimates of $1.86 by ($0.61). The business had revenue of $6.49 billion for the quarter, compared to analyst estimates of $6.85 billion. Eli Lilly and had a return on equity of 85.58% and a net margin of 19.58%. Eli Lilly and's revenue was down 3.7% on a year-over-year basis. During the same period in the prior year, the firm posted $1.87 EPS. On average, sell-side analysts anticipate that Eli Lilly and will post 7.96 earnings per share for the current year.

Eli Lilly and Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, September 9th. Stockholders of record on Monday, August 15th will be given a dividend of $0.98 per share. The ex-dividend date is Friday, August 12th. This represents a $3.92 annualized dividend and a dividend yield of 1.24%. Eli Lilly and's payout ratio is currently 62.52%.

Analyst Ratings Changes

Several research firms have issued reports on LLY. SVB Leerink started coverage on Eli Lilly and in a research note on Monday, May 23rd. They set an "outperform" rating and a $341.00 price objective for the company. JPMorgan Chase & Co. lifted their price target on shares of Eli Lilly and from $340.00 to $355.00 in a report on Wednesday, June 1st. Morgan Stanley upped their price objective on shares of Eli Lilly and from $369.00 to $395.00 and gave the stock an "overweight" rating in a research note on Friday, July 8th. Mizuho lifted their target price on shares of Eli Lilly and from $315.00 to $356.00 in a research note on Monday, May 2nd. Finally, Barclays increased their price target on Eli Lilly and from $333.00 to $355.00 and gave the stock an "overweight" rating in a research report on Thursday, July 7th. Three analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company's stock. According to data from MarketBeat.com, Eli Lilly and has a consensus rating of "Moderate Buy" and an average price target of $317.00.

Insider Activity

In related news, SVP Alonzo Weems sold 656 shares of the business's stock in a transaction that occurred on Wednesday, August 10th. The shares were sold at an average price of $304.50, for a total transaction of $199,752.00. Following the completion of the transaction, the senior vice president now owns 8,136 shares in the company, valued at $2,477,412. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, major shareholder Lilly Endowment Inc sold 89,458 shares of the firm's stock in a transaction dated Thursday, July 28th. The stock was sold at an average price of $332.85, for a total transaction of $29,776,095.30. Following the sale, the insider now owns 103,875,441 shares of the company's stock, valued at $34,574,940,536.85. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, SVP Alonzo Weems sold 656 shares of the business's stock in a transaction that occurred on Wednesday, August 10th. The shares were sold at an average price of $304.50, for a total value of $199,752.00. Following the completion of the transaction, the senior vice president now owns 8,136 shares of the company's stock, valued at $2,477,412. The disclosure for this sale can be found here. Insiders sold a total of 1,114,591 shares of company stock valued at $355,690,328 in the last ninety days. 0.12% of the stock is owned by insiders.